Jubilant Pharmova Q1 results, quarter to Jun 2026

NSE: JUBLPHARMABSE: 530019Pharmaceuticals & BiotechnologySmall Cap

Jubilant Pharmova Limited · Formerly Jubilant Life Sciences · Face value ₹1 · Listed Jun 1981 on BSE, Jun 2003 on NSE

₹923.80₹22.20 (2.35%)BSE ₹924.70

Share price at the NSE close on 30 Oct 2026. Previous close ₹946.00.

30 Oct: open ₹946.00, high ₹951.80, low ₹920.00

52-week range of traded prices to 30 Oct 2026

₹786.05Low, 9 Mar 2026₹1,183.00High, 4 Nov 2025

Market cap: ₹14,714 Cr422nd largest listed
P/E: 41.79
P/E without one-offs: 35.78
P/B: 2.07
Dividend yield: 0.54%
ROE: 5.3%
ROE without one-offs: 6.2%
ROCE: 7.3%
Debt to equity: 0.45
Volume, NSE: 56,22937.1% delivered

Jubilant Pharmova filed its Q1 results for the quarter to Jun 2026 on 10 Aug 2026 at 7:32 pm, consolidated: the company and its subsidiaries together.

Q1 results, quarter to Jun 2026

₹ crore.Jubilant Pharmova annual results and balance sheet

Revenue: ₹2,229 Cr+17.3% on a year ago · −2.6% on the quarter before
Operating profit: ₹248 Cr−14.4% on a year ago · −26.9% on the quarter before
Net profit: ₹56 Cr−45.0% on a year ago · −52.7% on the quarter before
Earnings per share: ₹3.57−45.0% on a year ago · −52.7% on the quarter before
Operating margin: 11.1%
Net margin: 2.5%

From revenue to net profit, ₹ crore

Revenue2,229
Materials and goods−749
Employee costs−754
Other expenses−479
Operating profit248
Depreciation−127
Other income+20
Finance costs−54
Profit before tax86
Tax−30
Net profit56

Jubilant Pharmova results by quarter

Consolidated: the company and its subsidiaries together. Latest quarter to Jun 2026. Results for the quarter to Sep 2026 are due by 14 Nov 2026, 45 days after it ends. Every company's dates are on the results calendar.Results filings and date

Revenue and net profit by quarter, ₹ crore

Revenue
Net profit
Loss

Peak revenue ₹2,290 Cr, quarter to Mar 2026; lowest ₹1,677 Cr, quarter to Dec 2023A loss in 1 of the 12 quarters shown

Operating and net margin by quarter, per cent

Operating margin
Net margin

₹ crore	Sep 2021	Dec 2021Q3	Mar 2022	Jun 2022Q1	Sep 2022	Dec 2022Q3	Mar 2023	Jun 2023Q1	Sep 2023	Dec 2023Q3	Mar 2024	Jun 2024Q1	Sep 2024	Dec 2024Q3Filed 31 Jan	Mar 2025Q4Filed 16 May	Jun 2025Q1Filed 29 Jul	Sep 2025Q2	Dec 2025Q3Filed 6 Feb	Mar 2026Q4	Jun 2026Q1Filed 10 Aug
Revenue from operations	1,657	1,311	1,514	1,452	1,600	1,553	1,678	1,587	1,680	1,677	1,759	1,732	1,752	1,822	1,929	1,901	1,966	2,123	2,290	2,229
	1,318	1,116	1,280	1,259	1,381	1,407	1,459	1,417	1,439	1,459	1,487	1,480	1,463	1,534	1,583	1,611	1,625	1,833	1,951	1,981
Materials and goods bought	439	273	415	387	483	478	530	520	557	536	527	562	555	574	626	618	597	716	713	749
Employee costs	509	525	510	529	535	568	534	548	532	582	555	553	564	560	591	591	636	706	767	754
Other expenses	369	318	355	343	363	361	395	350	349	342	405	366	344	400	367	402	392	410	471	479
Operating profit before depreciation	340	194	234	192	219	146	219	170	242	218	271	252	289	287	345	290	341	290	339	248
Operating margin	20.5%	14.8%	15.5%	13.3%	13.7%	9.4%	13.1%	10.7%	14.4%	13.0%	15.4%	14.5%	16.5%	15.8%	17.9%	15.2%	17.4%	13.6%	14.8%	11.1%
Depreciation and amortisation	100	93	101	95	94	94	271	90	97	95	101	91	91	91	95	98	105	121	117	127
Other income	4	6	10	11	13	9	4	9	10	36	14	14	22	9	12	12	10	21	24	20
Finance costs	35	37	40	40	42	51	56	62	66	71	73	71	61	56	53	49	50	56	57	54
Profit before one-off items and tax	209	70	104	69	96	10	−103	27	89	88	112	104	159	150	209	155	196	133	190	86
One-off items	0	0	0	0	−57	0	0	0	0	0	−169	396	−14	−19	−3	0	−6	−40	−14	0
Profit before tax	209	70	104	69	39	10	−103	27	89	88	−57	500	145	131	206	155	190	94	176	86
	65	19	47	22	31	25	14	19	36	35	8	18	42	30	55	52	70	38	57	30
Current tax	58	8	41	39	93	−4	53	14	35	45	108	26	40	32	115	38	36	22	66	30
Deferred tax	7	11	6	−17	−61	28	−39	5	1	−11	−100	−8	2	−3	−60	14	34	16	−9	0
Tax rate	31.2%	27.7%	44.6%	32.2%	80.6%	238.6%	–	72.2%	40.3%	39.4%	–	3.6%	29.0%	22.8%	26.5%	33.6%	37.0%	40.2%	32.2%	34.7%
Share of profit of joint ventures and associates	−1	0	1	0	−3	−2	17	−1	9	13	3	–	0	0	0	0	0	0	–	–
	143	51	59	47	5	−16	−101	6	62	66	−62	482	103	101	151	103	120	56	119	56
Belonging to the company's shareholders	143	51	60	47	5	−16	−98	6	63	67	−59	482	103	101	154	103	120	56	119	57
Belonging to outside owners of subsidiaries	0	0	0	0	−1	0	−3	0	0	0	−3	0	0	0	−2	0	0	0	0	0
Other comprehensive income	−15	31	73	116	67	72	−34	10	34	17	−7	−4	30	64	−5	41	160	62	282	−19
Total comprehensive income	128	82	132	163	72	56	−135	16	96	83	−68	478	133	164	147	144	280	118	401	37
Net margin	8.6%	3.9%	3.9%	3.2%	0.3%	−1.0%	−6.0%	0.4%	3.7%	4.0%	−3.5%	27.8%	5.8%	5.5%	7.8%	5.4%	6.1%	2.6%	5.2%	2.5%
Net margin without joint ventures and associates	8.7%	3.9%	3.8%	3.2%	0.5%	−0.9%	−7.0%	0.5%	3.2%	3.2%	−3.7%	–	5.9%	5.5%	7.8%	5.4%	6.1%	2.6%	–	–
Earnings per share	₹8.97	₹3.20	₹3.74	–	₹0.34	−₹0.98	−₹6.15	₹0.40	₹3.94	₹4.22	−₹3.69	₹30.44	₹6.47	₹6.37	₹9.71	₹6.49	₹7.59	₹3.52	₹7.55	₹3.57
Diluted earnings per share	₹8.97	₹3.20	₹3.74	–	₹0.34	−₹0.98	−₹6.15	₹0.40	₹3.94	₹4.20	−₹3.68	₹30.35	₹6.46	₹6.36	₹9.68	₹6.47	₹7.57	₹3.52	₹7.52	₹3.56

Earnings per share in rupees, restated for later splits and bonuses.

The quarter to Jun 2022 was restated in the company's filing of 24 Oct 2022. The table shows the restated figures.

Segment results by quarter

Consolidated, ₹ crore, quarters to Jun 2026.Jubilant Pharmova segment results by year

Radiopharma
Revenue, ₹ crore
741
752
818
832
820
841
895
869
897
934
990
1,022
Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26
Profit, ₹ crore
117
144
134
105
92
95
104
99
96
88
78
78
Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26
Contract Development and Manufacturing Organisation - Sterile Injectables
Revenue, ₹ crore
315
314
280
334
330
316
372
393
412
462
547
520
Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26
Profit, ₹ crore
36
17
40
39
70
33
76
43
71
36
56
7
Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26
Contract Research, Development and Manufacturing Organisation
Revenue, ₹ crore
289
264
291
249
281
299
344
311
313
306
335
326
Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26
Profit, ₹ crore
21
22
28
14
24
35
55
27
29
32
36
36
Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26
Allergy Immunotherapy
Revenue, ₹ crore
180
172
194
178
170
174
192
191
194
193
218
214
Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26
Profit, ₹ crore
84
60
74
62
45
47
87
61
75
46
90
64
Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26
Generics
Revenue, ₹ crore
172
199
201
156
173
200
157
166
167
226
214
173
Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26
Profit, ₹ crore
−73
−52
−60
−22
9
19
−29
0
0
11
17
−10
Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26
Proprietary Novel drugs
Revenue, ₹ crore
0
0
0
0
0
0
0
0
0
0
0
0
Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26
Profit, ₹ crore
−8
−5
−7
−6
−3
−5
−4
−6
−3
−3
−7
−8
Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26

₹ crore	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue of all businesses	1,698	1,701	1,783	1,749	1,774	1,830	1,960	1,930	1,982	2,121	2,303	2,256
Company revenue, as in its results	1,680	1,677	1,759	1,732	1,752	1,822	1,929	1,901	1,966	2,123	2,290	2,229
Revenue	741	752	818	832	820	841	895	869	897	934	990	1,022
Revenue growth	12.5%	22.7%	18.6%	20.5%	10.6%	11.8%	9.5%	4.4%	9.5%	11.1%	10.6%	17.7%
Profit	117	144	134	105	92	95	104	99	96	88	78	78
Profit growth	5.4%	335.3%	131.2%	62.6%	−21.4%	−34.2%	−22.4%	−5.8%	3.8%	−7.0%	−25.3%	−20.9%
Margin	15.8%	19.1%	16.4%	12.6%	11.2%	11.2%	11.6%	11.4%	10.6%	9.4%	7.9%	7.6%
Assets	2,823	2,852	2,968	2,895	2,889	3,014	2,880	2,882	3,048	3,165	3,679	3,857
Liabilities	754	645	794	699	698	732	918	920	888	997	1,239	1,259
Capital employed	2,069	2,207	2,173	2,196	2,191	2,281	1,963	1,962	2,160	2,168	2,440	2,599
Revenue	315	314	280	334	330	316	372	393	412	462	547	520
Revenue growth	−0.7%	6.4%	−19.3%	13.1%	4.8%	0.6%	33.1%	17.5%	24.6%	46.2%	46.8%	32.4%
Profit	36	17	40	39	70	33	76	43	71	36	56	7
Profit growth	−31.5%	−52.2%	−38.8%	90.1%	95.5%	90.8%	89.3%	11.7%	1.4%	9.3%	−26.5%	−83.1%
Margin	11.4%	5.5%	14.4%	11.6%	21.2%	10.5%	20.4%	11.0%	17.3%	7.9%	10.2%	1.4%
Assets	3,076	3,114	3,350	3,473	3,830	4,155	4,348	5,010	5,461	5,517	6,058	6,355
Liabilities	819	794	1,028	1,186	1,565	1,803	2,152	2,299	2,463	2,569	2,785	2,766
Capital employed	2,257	2,320	2,323	2,288	2,265	2,352	2,196	2,711	2,998	2,948	3,273	3,589
Revenue	289	264	291	249	281	299	344	311	313	306	335	326
Revenue growth	−18.0%	−12.3%	−8.5%	−15.9%	−2.8%	13.4%	18.2%	24.9%	11.1%	2.5%	−2.5%	4.6%
Profit	21	22	28	14	24	35	55	27	29	32	36	36
Profit growth	−59.0%	1.6%	−4.1%	−20.1%	13.1%	56.7%	95.4%	100.0%	20.3%	−9.4%	−34.4%	31.9%
Margin	7.4%	8.5%	9.7%	5.4%	8.6%	11.7%	16.0%	8.7%	9.3%	10.4%	10.8%	10.9%
Assets	1,649	1,606	1,597	1,571	1,569	1,574	1,746	1,724	1,754	1,837	1,773	1,767
Liabilities	262	232	248	205	251	246	396	382	385	442	442	456
Capital employed	1,387	1,374	1,349	1,365	1,318	1,329	1,350	1,342	1,369	1,395	1,331	1,311
Revenue	180	172	194	178	170	174	192	191	194	193	218	214
Revenue growth	15.8%	17.2%	14.0%	17.7%	−5.7%	0.9%	−0.9%	7.4%	14.1%	10.7%	13.4%	12.0%
Profit	84	60	74	62	45	47	87	61	75	46	90	64
Profit growth	68.6%	19.5%	38.0%	27.0%	−46.1%	−23.0%	18.0%	−1.1%	66.1%	−1.7%	3.6%	3.6%
Margin	46.4%	35.0%	38.0%	34.8%	26.5%	26.7%	45.2%	32.0%	38.6%	23.7%	41.3%	29.6%
Assets	518	531	566	565	605	482	798	563	572	608	631	624
Liabilities	72	55	63	68	76	57	96	78	96	96	131	105
Capital employed	445	476	504	497	529	425	702	485	476	512	500	519
Revenue	172	199	201	156	173	200	157	166	167	226	214	173
Revenue growth	6.0%	−11.4%	0.8%	−23.1%	0.3%	0.4%	−21.8%	6.7%	−3.4%	13.3%	36.3%	4.5%
Profit	−73	−52	−60	−22	9	19	−29	0	0	11	17	−10
Profit growth	–	–	–	–	–	–	–	–	–	−41.7%	–	–
Margin	−42.1%	−26.4%	−29.7%	−13.8%	5.2%	9.4%	−18.6%	−0.2%	−0.2%	4.8%	8.1%	−5.8%
Assets	1,692	1,729	1,438	1,233	1,234	1,231	1,162	1,203	1,210	1,289	1,242	1,179
Liabilities	247	262	243	283	270	250	240	259	215	268	259	242
Capital employed	1,445	1,467	1,196	950	964	981	922	944	994	1,022	983	937
	0	0	0	0	0	0	0	0	0	0	0	0
Profit	−8	−5	−7	−6	−3	−5	−4	−6	−3	−3	−7	−8
Assets	218	229	236	244	250	262	270	277	294	304	331	338
Liabilities	13	16	11	13	9	6	9	12	6	8	10	14
Capital employed	205	213	224	232	241	256	261	265	288	297	321	325
Revenue	8	11	11	10	10	11	7	13	16	15	15	14
Profit	0	0	0	0	−32	0	0	0	0	0	0	0
Assets	0	0	1,394	1,432	1,549	1,428	1,552	1,345	0	0	1,809	0
Liabilities	0	0	3,741	3,083	3,129	2,963	2,707	2,667	0	0	3,561	0

Profit is before tax and finance costs, the way companies report their segments.

Q1 results, quarter to Jun 2026

From revenue to net profit, ₹ crore

Jubilant Pharmova results by quarter

Revenue and net profit by quarter, ₹ crore

Operating and net margin by quarter, per cent

Segment results by quarter

Radiopharma

Contract Development and Manufacturing Organisation - Sterile Injectables

Contract Research, Development and Manufacturing Organisation

Allergy Immunotherapy

Generics

Proprietary Novel drugs